Blar i forfatter "Svardal, Asbjørn M."

Viser treff 1-4 av 4

    • The carnitine-butyrobetaine-TMAO pathway after cardiac transplant: Impact on cardiac allograft vasculopathy and acute rejection 

      Trøseid, Marius; Mayerhofer, Christiane Caroline; Broch, Kaspar; Arora, Satish; Svardal, Asbjørn M.; Hov, Johannes Espolin Roksund; Andreassen, Arne K.; Gude, Einar; Karason, Kristjan; Dellgren, Gøran; Berge, Rolf Kristian; Gullestad, Lars; Aukrust, Pål; Ueland, Thor (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-06-19)
      <p><i>BACKGROUND - </i>Alterations in the partly microbiota-dependent carnitine–γ-butyrobetaine (γBB)–trimethylamine N-oxide (TMAO) pathway have been linked to the progression of heart failure and atherosclerotic disease. We evaluated if circulating γBB, TMAO, and their common precursors carnitine and trimethyllysine (TML) were dysregulated after heart transplantation and associated with development ...

    • Major increase in microbiota-dependent proatherogenic metabolite TMAO one year after bariatric surgery 

      Trøseid, Marius; Hov, Johannes Espolin Roksund; Nestvold, Torunn Kristin; Thoresen, Hanne; Berge, Rolf Kristian; Svardal, Asbjørn M.; Lappegård, Knut Tore (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-04-15)
      Background: Trimethylamine-N-oxide (TMAO) is formed in the liver from trimethylamine (TMA), a product exclusively generated by the gut microbiota from dietary phosphatidylcholine and carnitine. An alternative pathway of TMAO formation from carnitine is via the microbiota-dependent intermediate g-butyrobetaine (gBB). Elevated TMAO levels are associated with cardiovascular disease (CVD), but little ...

    • Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial 

      Awoyemi, Ayodeji Olawale; Mayerhofer, Cristiane; Felix, Alex S.; Hov, Johannes Espolin Roksund; Moscavitch, Samuel D.; Lappegård, Knut Tore; Hovland, Anders; Halvorsen, Sigrun; Halvorsen, Bente; Gregersen, Ida; Svardal, Asbjørn M.; Berge, Rolf Kristian; Hansen, Simen Hyll; Götz, Alexandra; Holm, Kristian; Aukrust, Pål; Åkra, Sissel; Seljeflot, Ingebjørg; Solheim, Svein; Lorenzo, Andrea; Gullestad, Lars; Trøseid, Marius; Broch, Kaspar (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-07-28)
      Background - The gut microbiota represents a potential treatment target in heart failure (HF) through microbial metabolites such as trimethylamine N-oxide (TMAO) and systemic inflammation. Treatment with the probiotic yeast Saccharomyces boulardii have been suggested to improve left ventricular ejection fraction (LVEF).<p> <p>Methods - In a multicentre, prospective randomized open label, blinded ...

    • Rosuvastatin alters the genetic composition of the human gut microbiome 

      Kummen, Martin; Solberg, Ole Geir; Larsen, Christopher Storm; Holm, Kristian; Ragnarsson, Asgrimur; Trøseid, Marius; Vestad, Beate; Skårdal, Rita; Yndestad, Arne; Ueland, Thor; Svardal, Asbjørn M.; Berge, Rolf Kristian; Seljeflot, Ingebjørg; Gullestad, Lars; Karlsen, Tom Hemming; Aaberge, Lars; Aukrust, Pål; Hov, Johannes Espolin Roksund (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-03-25)
      The gut microbiome contributes to the variation of blood lipid levels, and secondary bile acids are associated with the effect of statins. Yet, our knowledge of how statins, one of our most common drug groups, affect the human microbiome is scarce. We aimed to characterize the effect of rosuvastatin on gut microbiome composition and inferred genetic content in stool samples from a randomized controlled ...